Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tenormin/myocardial infarction trial

Executive Summary

Treatment with Stuart's Tenormin (atenolol) in the early stages of suspected myocardial infarction reduced mortality by 15% compared to standard therapy, according to a study reported in the July 12 Lancet. The ISIS (International Study on Infarcet Survival) trial, conducted by Peter Sleight of Oxford University, was three and a half years in duration and involved 16,00 patients from 247 centers in 14 countries. Press release on study says "the most beneficial effects on mortality occurred in the first 48 hours" among patients who received I.V. beta blocker.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS010457

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel